FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma

Blood

Volumn 107, Issue 1, 2006, Pages 52-59

  Hutchings, Martin ^a   Loft, Annika ^b   Hansen, Mads ^b   Pedersen, Lars Møller ^b   Buhl, Thora ^b   Jurlander, Jesper ^b   Buus, Simon ^b   Keiding, Susanne ^b   D'Amore, Francesco ^b   Boesen, Anne Marie ^b   Berthelsen, Anne Kiil ^b   Specht, Lena ^b  

^a Mental Health Services CPH   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME;

EID: 30144432586     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-06-2252     Document Type: Article

References (41)

1. Mauch PM, Armitage JO, Diehl V, Hoppe RT, Weiss LM. Hodgkin's Disease. Philadelphia, PA: Lippincott Williams & Wilkins; 1999.
2. Hancock SL, Hoppe RT. Long-term complications of treatment and causes of mortality after Hodgkin's disease. Semin Radiat Oncol. 1996;6:225-242.
3. Henry-Amar M, Somers R. Survival outcome after Hodgkin's disease: a report from the international data base on Hodgkin's disease. Semin Oncol. 1990;17:758-768.
4. Hoppe RT. Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol. 1997;8(suppl 1):115-118.
5. Specht L, Gray RG, Clarke MJ, Peto R. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients: International Hodgkin's Disease Collaborative Group. J Clin Oncol. 1998;16:830-843.
6. Kogel KE, Sweetenham JW. Current therapies in Hodgkin's disease. Eur J Nucl Med Mol Imaging. 2003;30(suppl 1):S19-S27.
7. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339:1506-1514.
8. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989;7:1630-1636.
9. Specht L. Prognostic factors in Hodgkin's disease. Semin Radiat Oncol. 1996;6:146-161.
10. Oza AM, Ganesan TS, Leahy M, et al. Patterns of survival in patients with Hodgkin's disease: long follow up in a single centre. Ann Oncol. 1993;4:385-392.
11. Rankin SC. Assessment of response to therapy using conventional imaging. Eur J Nucl Med Mol Imaging. 2003;30(suppl 1):S56-S64.
12. Gupta RK, Gospodarowicz MK, Lister TA. Clinical evaluation and staging. In: Mauch P, Armitage JO, Diehl V, Hoppe R, Weiss LM, eds. Hodgkin's Disease. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:223-240.
13. Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol. 1988;6:931-933.
14. Jerusalem G, Beguin Y, Fassotte MF, et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica. 2000;85:613-618.
15. Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma-comparison with CT. Leuk Lymphoma. 2000;39:543-553.
16. Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol. 2002;13:1356-1363.
17. Hoekstra OS, Ossenkoppele GJ, Golding R, et al. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med. 1993;34:1706-1710.
18. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med. 2002;43:1018-1027.
19. Torizuka T, Nakamura F, Kanno T, et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 2004;31:22-28.
20. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005;16:1514-1523.
21. Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106:1376-1381.
22. Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005;16:1160-1168.
23. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
24. Glimelius B, Specht L, Nome O, Tuurpeeniemi-Hujanen T. Treatment of adult patients with early stage Hodgkin's disease. Available at: http://www.roc.se/ PDFfiles/Vardprogram/Protokoll_HD.PDF. Accessed July 18, 2005.
25. Woodard HQ, Bigler RE, Freed B. Expression of tissue isotope distribution [letter]. J Nucl Med. 1975;16:958-959.
26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
27. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II, analysis and examples. Br J Cancer. 1977;35:1-39.
28. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187-220.
29. Landau S, Everitt BS. A Handbook of Statistical Analyses using SPSS. Boca Raton, FL: Chapman & Hall/CRC; 2004.
30. Collett D. Modelling Survival Data in Medical Research. 2nd ed. Boca Raton, FL: Chapman & Hall/CRC; 2003.
31. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348:2386-2395.
32. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993;341:1051-1054.
33. Yuen AR, Rosenberg SA, Hoppe RT, Halpern JD, Horning SJ. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood. 1997;89:814-822.
34. Sweetenham JW, Carella AM, Taghipour G, et al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol. 1999;17:3101-3109.
35. Front D, Bar-Shalom R, Mor M, et al. Hodgkin disease: prediction of outcome with 67Ga scintigraphy after one cycle of chemotherapy. Radiology. 1999;210:487-491.
36. Salloum E, Brandt DS, Caride VJ, et al. Gallium scans in the management of patients with Hodgkin's disease: a study of 101 patients. J Clin Oncol. 1997;15:518-527.
37. Hagemeister FB, Purugganan R, Podoloff DA, et al. The gallium scan predicts relapse in patients with Hodgkin's disease treated with combined modality therapy. Ann Oncol. 1994;5(suppl 2):59-63.
38. Friedberg JW, Fischman A, Neuberg D, et al. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma. 2004;45:85-92.
39. Spaepen K, Stroobants S, Dupont P, et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol. 2001;115:272-278.
40. Hueltenschmidt B, Sautter-Bihl ML, Lang O, et al. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer. 2001;91:302-310.
41. Romer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood. 1998;91:4464-4471.